Israel - English - Ministry of Health

eldan electronic instruments co ltd, israel - gadoteric acid - solution for injection - gadoteric acid 279.3 mg / 1 ml - gadoteric acid - enhancement of contrast in magnetic resonance imaging.aencephalic and spinal pathologies: brain tumours, tumours of the spine and the surrounding tissue, intervertebral disk prolapse infectious diseases.abdominal pathologies: primary and secondary liver tumours.osteo-articular pathology: bone and soft tissue tumours synovial diseases.magnetic resonance imaging for angiography.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

ge healthcare (pty) ltd - injection - see ingredients - each 1,0 ml solution contains gadoteric acid 279,3 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml - concentrate for injection - 12.5 mg/ml - active: dobutamine hydrochloride 14.01 mg/ml equivalent to dobutamine 12.5 mg/ml excipient: hydrochloric acid nitrogen sodium hydroxide sodium metabisulfite water for injection - dobutamine hydrochloride is indicated when inotropic support is necessary for the treatment of patients with hypoperfusion states in whom cardiac output is insufficient to meet circulatory demands. dobutamine hydrochloride is also indicated when inotropic support is required for the treatment of patients in whom abnormally increased ventricular filling pressures introduce the risk of pulmonary congestion and oedema. conditions which may precipitate such situations include the following hypoperfusion states: initially cardiac in origin a. acute heart failure 1. acute myocardial infarction 2. cardiogenic shock 3. following cardiac surgery 4. medicine-induced depression of cardiac contractility such as that which occurs in excessive ?- adrenergic receptor blockade. b. chronic heart failure 1. acute decompensation of chronic congestive heart failure 2. temporary inotropic support in advanced chronic congestive heart failure, as an adjunct to therapy with convention

New Zealand - English - Medsafe (Medicines Safety Authority)

ge healthcare limited - gadoteric acid 279.3 mg/ml (contains excess of dota/tetraxetan) - solution for injection - 0.5 mmol/ml - active: gadoteric acid 279.3 mg/ml (contains excess of dota/tetraxetan) excipient: meglumine water for injection - magnetic resonance imaging for: - cerebral and spinal disease - diseases of the vertebral column - other whole-body pathologies (including angiography of the non-coronary arteries)

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

ge healthcare as, norway - gadoteric acid - solution for injection - 279.3 mg/0.5 mmol

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

ge healthcare as, norway - gadoteric acid - solution for injection - 279.3 mg/0.5 mmol

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - fluconazole 2 mg/ml - solution for infusion - 0.2% w/v - active: fluconazole 2 mg/ml excipient: hydrochloric acid sodium chloride water for injection - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole-claris can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Ireland - English - HPRA (Health Products Regulatory Authority)

claris lifesciences (uk) limited - bupivacaine hydrochloride - solution for injection - 2.5 mg/ml - amides